| NCT ID | NCT07457151 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AstraZeneca |
| Condition | Paroxysmal Nocturnal Hemoglobinuria |
| Study Type | OBSERVATIONAL |
| Enrollment | 8 participants |
| Start Date | 2026-04-10 |
| Primary Completion | 2028-06-27 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 8 participants in total. It began in 2026-04-10 with a primary completion date of 2028-06-27.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
As part of a post-approval commitment, the Korean health authority requests a study to characterize safety and effectiveness in patients who are treated with Danicopan as an add-on to ravulizumab or eculizumab in normal clinical practice settings. This study is designed to assess the known safety profile or identify previously unsuspected adverse reactions and to evaluate the effectiveness of Danicopan under conditions of routine daily medical practice in Korea.
Eligibility Criteria
Inclusion Criteria: 1. Patients eligible for and treated with Danicpan as add-on therapy to a C5 inhibitor (Eculizumab or Ravulizumab) in patient with PNH in Korea 2. Provision of a signed and dated written informed consent by the patient or their legally acceptable representative Exclusion Criteria: 1. Participation in any concurrent interventional trials during the period of study drug treatment 2. Other off-label indications according to the approved label in Korea
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07457151 clinical trial?
This trial is open to participants of all sexes, studying Paroxysmal Nocturnal Hemoglobinuria. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07457151 currently recruiting?
Yes, NCT07457151 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.
Where is the NCT07457151 trial being conducted?
This trial is being conducted at Hwasun-gun, South Korea, Seoul, South Korea.
Who is sponsoring the NCT07457151 clinical trial?
NCT07457151 is sponsored by AstraZeneca. The trial plans to enroll 8 participants.